Kardigan, Inc. Common Stock 12th Annual Cantor Fitzgerald Global Healthcare Conference

Appreciate you having us here.

It's good to be public.

Would love to. You guys are pressed from long timelines, capital-intensive approaches. We're seeing a lot of this even today, recently over the last month or so. As a result, we see generally a lack of investment in the world's number one killer of men and women. So we created Kardigan to address that specifically. We've designed the company in order to focus on the root cause of disease, something that the lack of which leads to these long and costly outcome studies. Also moves you further away from being able to get to actual disease-modifying potential in these therapies, which is ultimately what patients need. It gives us the opportunity to do faster trials, to do them with smaller patients, things we've done before in previous companies, but now we've really started Kardigan up in a way to do this at a much larger scale.

We've added technologies and some tools that weren't available to us before, and you'll hear from my teammates here on how exactly we're doing that. A company called Prolaio that we started and looking at adaptive, enriching designs. All of this has resulted in the company now having a pretty robust late-stage pipeline in three areas that are in desperate need of new medicines, dilated cardiomyopathy, aortic stenosis, and acute severe hypertension. We've set up the company in a way to be a real platform to make it easy for investors, in part, to participate in the number one therapeutic segment on the planet, which I think is tricky for people to really lean in hard on, and we're going to try and make that easy for you all.

I think generally speaking, in clinical practice in cardiology, we're still leaning very much on clinical history, on symptoms, on imaging, in some instances also on biomarkers. It is changing a bit, I think, relative to at least the last time I was involved in developing new medicines in cardiology. We've seen some successes, both in terms of what we've done with drugs like mavacamten and CAMZYOS, but what we're seeing in the amyloid cardiomyopathy space. A little bit more attention is now being placed on profiling patients. Genetics is an important part of that, but importantly, to moving maybe towards more real-world continuous snapshots rather than single annual snapshots of people's conditions. Imaging is fantastic. The heart is just giving us a wealth of information, both in terms of its heart rate, ECGs, we get step counts, et cetera.

We get drugs approved by the FDA on improvements in symptoms and functions. These are things that we can measure much more continuously. If you couple that with genetics where we are seeing upticks, there's been some really great successes, I think. The amyloid space is a great story there about improving diagnosis and really making a difference for patients. We're seeing the trends, but there's more work to be done, and we're going to help kind of push that along a little bit.

Yeah. It's a really cool part of our company. We've developed an organization that is effectively its own entity, owned by Kardigan. But we've got 70 or so data scientists, software engineers, et cetera, who take data from multiple different sources, continuous data, primarily from electronic medical records, from smartphones that patients have, so patient-reported outcomes, and from wearables that are FDA-cleared. We've established now an FDA-grade platform that has five algorithms approved. We've got millions of years of patients' worth of data. We use these to paint a much more higher resolution, comprehensive picture of a patient's journey on an individual basis. How is their disease progressing? What's changing? How do things change with interventions? How we're deploying that kind of tool today. I think this is uniquely exciting to cardiology.

I think these things are difficult to do in other disease areas, but in cardiology, we are able to get these data fairly easily that are already correlated to disease risk and benefit. We are using that to enrich our patient populations in our clinical trials. All of our programs are deploying these tools. Study participants get a kit that has this equipment in it. They love it, right? They have a say kind of in their own health condition. The data that we get is really powerful, and it augments the in-clinic data that we have, as well as some other tools that we can use as well. I think if you imagine in the future, you can think about more decentralized studies where we can use real-world endpoints. For example, Prolaio has a clearance for something called eVO2, which is a surrogate to peak VO2.

If we can avoid the need to go into a clinic, do a cumbersome cardiopulmonary exercise test, by the way, it was an endpoint that we used in hypertrophic CM, it would really be a game changer for patients, participants in our clinical trials, but also just giving us better data on a more continuous basis, moving us away from the snapshot. You will see it in our studies today. As far as endpoints are concerned, it is more exploratory in nature today. We are building towards using those tools for primaries. It is really important from an enrichment standpoint and also from a profiling of patients, particularly in terms of their response to our candidates and their disease condition.